Design and Analysis of Clinical Trials with Time-to-Event Endpoints

Design and Analysis of Clinical Trials with Time-to-Event Endpoints

Peace, Karl E.

Taylor & Francis Ltd

09/2018

616

Mole

Inglês

9781138372665

15 a 20 dias

1140

Descrição não disponível.
Overview of Time-to-Event Endpoint Methodology. Design (and Monitoring) of Clinical Trials with Time-to-Event Endpoints. Overview of Time-to-Event Parametric Methods. Overview of Semiparametric Inferential Methods for Time-to-Event Endpoints. Overview of Inferential Methods for Categorical Time-to-Event Data. Overview of Bayesian Inferential Methods Including Time-to-Event Endpoints. An Efficient Alternative to the Cox Model for Small Time-to-Event Trials. Estimation and Testing for Change in Hazard for Time-to-Event Endpoints. Overview of Descriptive and Graphical Methods for Time-to-Event Data. Design and Analysis of Analgesic Trials. Design and Analysis of Analgesic Trials with Paired Time-to-Event Endpoints. Time-to-Event Endpoint Methods in Antibiotic Trials. Design and Analysis of Cardiovascular Prevention Trials. Design and Analysis of Antiviral Trials. Cure Rate Models with Applications to Melanoma and Prostate Cancer Data. Parametric Likelihoods for Multiple Nonfatal Competing Risks and Death, with Application to Cancer Data. Design, Summarization, Analysis, and Interpretation of Cancer Prevention Trials. LASSO Method in Variable Selection for Right-Censored Time-to-Event Data with Application to Astrocytoma Brain Tumor and Chronic Myelogenous Leukemia. Selecting Optimal Treatments Based on Predictive Factors. Application of Time-to-Event Methods in the Assessment of Safety in Clinical Trials. Design and Analysis of Chronic Carcinogenicity Studies of Pharmaceuticals in Rodents. Design and Analysis of Time-to-Tumor Response in Animal Studies: A Bayesian Perspective. Index.
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Interim Analysis;Cox Model;clinical trials;Time Dependent Covariates;parametric method;Cox Proportional Hazards Model;Cure Rate Models;LASSO method;Gamma Frailty Model;Karl E. Peace;Accelerated Failure Time Model;cardiovascular prevention;Proportional Hazards Assumption;biomedical research;Invasive Breast Cancer;Hazard Function;Super Learner;Va Ri;Partial Likelihood;Data Set;Baseline Hazards;Regression Models;Posterior Distribution;HLA Match;Log Hazard Ratio;Proportional Hazards Model;PBMC Assay;PFS Rate;Tied Event Times;Median PFS;Estimated Cure Rates